Bbv154
- All
- News
-
Bharat Biotech Says Intranasal Covid Vaccine Found Safe In Booster Trials
- Monday August 15, 2022
- India News | Press Trust of India
Bharat Biotech International Ltd (BBIL) on Monday said it has completed the phase-III and booster dose trials for its intranasal Covid-19 vaccine BBV154, and it has proven to be safe.
- www.ndtv.com
-
Bharat Biotech Seeks Approval For Phase 3 Trial Of Intranasal Shots As Boosters
- Monday December 20, 2021
- India News | Press Trust of India
Bharat Biotech has sought the Drug Controller General of India's approval to conduct phase-3 trials of its intranasal vaccine (BBV154) against Covid to be used as a booster dose, sources said on Monday.
- www.ndtv.com
-
Bharat Biotech's 1st Nasal Covid Vaccine Gets Phase 2/3 Trial Nod
- Friday August 13, 2021
- India News | Reported by Sunil Prabhu, Edited by Harish Pullanoor
BBV154, developed by Bharat Biotech, is India's first intranasal vaccine to receive regulatory nod for late-stage clinical trials from the Biotechnology Industry Research Assistance Council's (BIRAC) under the Department of Biotechnology.
- www.ndtv.com
-
Nasal Covid Vaccine Candidate In Early Stage Of Development: Centre
- Tuesday March 9, 2021
- India News | Press Trust of India
An intranasal vaccine candidate (BBV154), being developed by Bharat Biotech, is in early clinical stage of development in India, Minister of State for Health Ashwini Choubey told the Rajya Sabha on Tuesday.
- www.ndtv.com
-
Bharat Biotech Says Intranasal Covid Vaccine Found Safe In Booster Trials
- Monday August 15, 2022
- India News | Press Trust of India
Bharat Biotech International Ltd (BBIL) on Monday said it has completed the phase-III and booster dose trials for its intranasal Covid-19 vaccine BBV154, and it has proven to be safe.
- www.ndtv.com
-
Bharat Biotech Seeks Approval For Phase 3 Trial Of Intranasal Shots As Boosters
- Monday December 20, 2021
- India News | Press Trust of India
Bharat Biotech has sought the Drug Controller General of India's approval to conduct phase-3 trials of its intranasal vaccine (BBV154) against Covid to be used as a booster dose, sources said on Monday.
- www.ndtv.com
-
Bharat Biotech's 1st Nasal Covid Vaccine Gets Phase 2/3 Trial Nod
- Friday August 13, 2021
- India News | Reported by Sunil Prabhu, Edited by Harish Pullanoor
BBV154, developed by Bharat Biotech, is India's first intranasal vaccine to receive regulatory nod for late-stage clinical trials from the Biotechnology Industry Research Assistance Council's (BIRAC) under the Department of Biotechnology.
- www.ndtv.com
-
Nasal Covid Vaccine Candidate In Early Stage Of Development: Centre
- Tuesday March 9, 2021
- India News | Press Trust of India
An intranasal vaccine candidate (BBV154), being developed by Bharat Biotech, is in early clinical stage of development in India, Minister of State for Health Ashwini Choubey told the Rajya Sabha on Tuesday.
- www.ndtv.com